Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 20, 2025 860 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR Dabrafenib–Trametinib Combination Approved for Solid Tumors with BRAF Mutations July 21, 2022 Alectinib Approved as an Adjuvant Treatment for Lung Cancer May 8, 2024 EMA Recommends Extension of Indications for Amivantamab May 6, 2024 Adjusting to the Challenges of Life After Cancer: An Expert Perspective May 5, 2022 Load more HOT NEWS GreaterGood Partners with Organization of Hope to Deliver Toys and Necessities... 5-Yr-Old Has Cutest Celebration With Big Brother After Being Declared Cancer-Free. FDA Approves Atezolizumab for BRAF V600 Mutation Positive Unresectable or Metastatic... Fertility Preservation Safe for Young Women with Breast Cancer
